Integral Health Asset Management LLC Buys 40,000 Shares of Agilent Technologies, Inc. $A

Integral Health Asset Management LLC lifted its stake in shares of Agilent Technologies, Inc. (NYSE:A) by 80.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 90,000 shares of the medical research company’s stock after buying an additional 40,000 shares during the quarter. Integral Health Asset Management LLC’s holdings in Agilent Technologies were worth $11,552,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in A. Envestnet Asset Management Inc. boosted its position in shares of Agilent Technologies by 3.8% in the 3rd quarter. Envestnet Asset Management Inc. now owns 607,914 shares of the medical research company’s stock worth $78,026,000 after purchasing an additional 22,498 shares in the last quarter. CCLA Investment Management raised its position in shares of Agilent Technologies by 10.5% in the 3rd quarter. CCLA Investment Management now owns 1,027,970 shares of the medical research company’s stock worth $131,909,000 after purchasing an additional 97,312 shares during the last quarter. Osaic Holdings Inc. boosted its stake in Agilent Technologies by 35.5% in the 2nd quarter. Osaic Holdings Inc. now owns 68,053 shares of the medical research company’s stock worth $8,017,000 after purchasing an additional 17,817 shares in the last quarter. Fenimore Asset Management Inc grew its position in Agilent Technologies by 224.2% during the 3rd quarter. Fenimore Asset Management Inc now owns 586,500 shares of the medical research company’s stock valued at $75,277,000 after purchasing an additional 405,620 shares during the last quarter. Finally, First Horizon Corp bought a new stake in Agilent Technologies during the 3rd quarter valued at about $1,378,000.

Agilent Technologies Stock Performance

NYSE:A opened at $111.60 on Friday. The stock has a 50-day simple moving average of $130.34 and a two-hundred day simple moving average of $135.71. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.59 and a current ratio of 2.07. Agilent Technologies, Inc. has a 52-week low of $96.43 and a 52-week high of $160.27. The firm has a market capitalization of $31.54 billion, a PE ratio of 24.64, a P/E/G ratio of 2.35 and a beta of 1.31.

Agilent Technologies (NYSE:A) last posted its quarterly earnings data on Wednesday, February 25th. The medical research company reported $1.36 earnings per share for the quarter, missing analysts’ consensus estimates of $1.37 by ($0.01). The company had revenue of $1.80 billion for the quarter, compared to analysts’ expectations of $1.81 billion. Agilent Technologies had a net margin of 18.26% and a return on equity of 24.49%. The firm’s quarterly revenue was up 7.0% on a year-over-year basis. During the same period in the previous year, the firm earned $1.31 earnings per share. Agilent Technologies has set its FY 2026 guidance at 5.900-6.040 EPS and its Q2 2026 guidance at 1.390-1.420 EPS. Analysts forecast that Agilent Technologies, Inc. will post 5.58 EPS for the current year.

Agilent Technologies Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 22nd. Investors of record on Tuesday, March 31st will be paid a dividend of $0.255 per share. The ex-dividend date is Tuesday, March 31st. This represents a $1.02 dividend on an annualized basis and a dividend yield of 0.9%. Agilent Technologies’s payout ratio is 22.52%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on A shares. Citigroup boosted their price objective on shares of Agilent Technologies from $165.00 to $185.00 and gave the stock a “buy” rating in a report on Tuesday, November 25th. Wells Fargo & Company cut their target price on Agilent Technologies from $175.00 to $165.00 and set an “overweight” rating on the stock in a research note on Thursday, February 26th. The Goldman Sachs Group started coverage on Agilent Technologies in a report on Tuesday, December 9th. They issued a “buy” rating and a $170.00 target price for the company. UBS Group decreased their price target on Agilent Technologies from $180.00 to $165.00 and set a “buy” rating for the company in a research note on Thursday, February 26th. Finally, HSBC assumed coverage on Agilent Technologies in a report on Tuesday, January 20th. They set a “buy” rating and a $180.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $161.20.

Agilent Technologies Company Profile

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.